INTRAVENOUS VERSUS ORAL CLOMIPRAMINE IN OBSESSIVE COMPULSIVE DISORDER

静脉注射与口服氯米帕明治疗强迫症的比较

• 批准号: 6115008
• 负责人: LORRIN M. KORAN
• 金额: $ 4.03万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115008
• 关键词: body temperature; clinical research; clinical trials; clomipramine; drug administration routes; drug screening /evaluation; human subject; human therapy evaluation; intravenous administration; mental disorder chemotherapy; obsessive compulsive disorder; oral administration

This double-blind study of 20 patients with obsessive-compulsive disorder (OCD) tests the hypothesis that; 1) Intravenous pulse loading of clomipramine (150 mg Day 1, 200 mg Day 2) will produce a larger decrease in symptoms of OCD than will identical oral doses; and 2) the larger the drop in core body temperature produced by the first dose of clomipramine, the more likely the patient's OCD symptoms will respond.

20例强迫症患者的双盲对照研究 强迫症(OCD)测试以下假设：1)静脉脉搏负荷 氯丙咪嗪(150毫克，第1天，200毫克，第2天)会产生更大的 强迫症症状的减少将超过相同的口服剂量；以及2) 较大的核心体温下降产生的第一剂 氯丙咪嗪，患者的强迫症症状就越有可能有反应。